AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01137578
Drug: Magnetic Resonance Imaging with Contrast
RxNorm normalized name: Contrased
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
Trial: NCT04438096
Drug: 100 mg
RxNorm normalized name: urea 100 MG
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One 100 mg pill and two placebo pills (QD) will be orally administered for 12 weeks
Trial: NCT04438096
Drug: 200 mg
RxNorm normalized name: RNA 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two 100 mg pills and one placebo pill (QD) will be orally administered for 12 weeks
Trial: NCT04438096
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Three placebo pills (QD) will be orally administered for 12 weeks
Trial: NCT01805765
Drug: Qing'E pills
FDA approved: no
EMA approved: no
PMDA approved: no
Description: composed of eucommia, psoralen, walnuts and garlic
Trial: NCT01594775
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: two-times daily self-administration of nasal spray containing placebo during five days after wounding.
Trial: NCT03454126
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as specified in the treatment arm.
Trial: NCT02519140
Drug: Cook Medical EMR Gel
RxNorm normalized name: egg shell, cooked
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cook Medical EMR Gel will be injected submucosally into ex-vivo gastric or colonic tissue specimens
Trial: NCT01518153
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5 mg/m2 dosed based on actual body surface area and administered intravenously on days +1, +3, +6.
Trial: NCT03775928
Drug: capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: capecitabine 1000mg/m2 bid d1-d14
Trial: NCT03089138
Drug: Regan Tangjiang
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The treatment duration is 3 consecutive days.
Trial: NCT02564055
Drug: GSK2894512 0.5% Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5% (5 mg/g) GSK2894512 will be supplied as white to off-white cream to be applied topically
Trial: NCT02564055
Drug: Vehicle cream
RxNorm normalized name: vehicle cream base no.160
FDA approved: no
EMA approved: no
PMDA approved: no
Description: White to off-white vehicle cream base to be applied topically
Trial: NCT02766673
Drug: Sterile Saline
RxNorm normalized name: Aqua Care Sterile Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will receive a dose of study medication every 4 hours for 24 total hours
Trial: NCT03376555
Drug: Acetylcholine (ACh) Dose Response
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probe 1. Lactated Ringer's only (control) Probe 2. Lactated Ringer's + N-G-nitro-L-arginine methyl ester (LNAME) Probe 3. Lactated Ringer's + Ascorbate Probe 4. Lactated Ringer's + Tempol Probe 5. Lactated Ringer's + Apocynin
Trial: NCT00625651
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inactive dummy AMG 655 (to maintain blind)
Trial: NCT00625651
Drug: Modified FOLFOX6
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination treatment comprising oxaliplatin (85 mg/m2), leucovorin (400 mg/m2) and bolus 5-FU (400 mg/m2) and continuous IV 5-FU (2400 mg/m2)\] administered by intravenous infusion once every 14 days (+3 days)
Trial: NCT01714661
Drug: EVP-6124
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arms 1, 2
Trial: NCT01714661
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 3
Trial: NCT00612872
Drug: [123I]CLINDE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects will be injected with up to 5 mCi and not to exceed 5.5 (not \>10% of 5 mCi limit) of 123-I CLINDE followed by serial SPECT imaging.
Trial: NCT00704899
Drug: Amitryptiline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amitryptiline 25mg once daily
Trial: NCT00438672
Drug: Placebo Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Injection without steroid
Trial: NCT00565487
Drug: Capecitabine, Tarceva
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Capecitabine is a self-administered (oral) medication \& will be dose escalated and administered in four dose levels: Level I - 600 mg/m2 bid; Level II - 700 mg/m2 bid; Level III - 825 mg/m2 bid; Level IV - 925 mg/m2 bid. Tarceva will be self-administered(orally) in an open-label, unblinded manner to all patients enrolled in the study. During the treatment period, patients will receive single agent Tarceva 100 mg/day. Treatment of Capecitabine \& Tarceva is continued daily until the completeness of the radiation or toxicity.
Trial: NCT00422812
Drug: Inhaled Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Placebo
Trial: NCT00422812
Drug: Inhaled PCZ 5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Prochlorperazine 5 mg
Trial: NCT00422812
Drug: Inhaled PCZ 7.5 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Prochlorperazine 7.5 mg
Trial: NCT00422812
Drug: Inhaled PCZ 10 mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Staccato Prochlorperazine 10 mg
Trial: NCT03591653
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02480686
Drug: SOF+PEG+RBV
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sofosbuvir (SOF) 400 mg tablet is administered orally once daily; Pegylated interferon alfa-2a (PEG) 180 μg was administered once weekly by subcutaneous injection; Ribavirin (RBV) was administered as a tablet orally according to body weight (\< 75kg = 1000 mg and ≥ 75 kg = 1200 mg).
Trial: NCT00771875
Drug: Acetaminophen
RxNorm normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be premedicated with acetaminophen prior to dosing per institution standard of care.
Trial: NCT04531072
Drug: Artemether-lumefantrine
RxNorm normalized name: artemether-lumefantrine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Safety and efficacy evaluation during concurrent use of artemether-lumefantrine and atazanavir-ritonavir based antiretroviral therapy
Trial: NCT00652925
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Higher dose, 6 mg/kg/dose BID
Trial: NCT00652925
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Active drug at lower dose
Trial: NCT00652925
Drug: Naproxen
RxNorm normalized name: Naproxen
DrugBank: Naproxen (DB00788)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Control comparator, 15 mg/kg/dy target dose
Trial: NCT00507026
Drug: IV Diclofenac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV Diclofenac q6h
Trial: NCT00507026
Drug: IV ketorolac
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV ketorolac q6h
Trial: NCT00507026
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo q6h
Trial: NCT01453400
Drug: Acetylsalicylic Acid (Aspirin, BAY1019036) + placebo
RxNorm normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single dose, 2 x 500 mg fast release aspirin tablets (1000 mg) + 2 x placebo acetaminophen caplets
Trial: NCT01453400
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single dose, 2 x placebo Acetaminophen caplets + 2 x placebo fast release Aspirin tablets
Trial: NCT03345576
Drug: Testosterone and standard NMES
RxNorm normalized name: testosterone and estrogen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twelve patients will undergo 1 year of supervised training examining the effects of testosterone replacement therapy (TRT) and standard surface neuromuscular electrical stimulation (NMES) in persons with denervated spinal cord injury.
Trial: NCT00982982
Drug: Placebo (control)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control: small amount of alcohol intravenous (quarter teaspoon), with no THC
Trial: NCT01817322
Drug: Prednisolone OR methylprednisolone OR deflazacort injected both control group and experimental group
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg IV Injection in OP Day and 250 mg IV injection in POD1(1 Post op day). And then the drug dose is gradually reduced following the study institution's protocol. But the subject must be take the dose of 5mg of the drug per one day. The drug dose should be controlled on the basis of 5mg of Prednisolone. It can be used with the same dose of methylprednisolone 4 mg or deflazacort 6 mg.
Trial: NCT01397929
Drug: BAL101553
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration
Trial: NCT01254305
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo capsules, oral administration, once daily dosing
Trial: NCT00004940
Drug: cysteine hydrochloride
RxNorm normalized name: Cysteine Hydrochloride
DrugBank: Cysteine (DB00151)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04310930
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adults: Intravenous amikacin 5mg/kg once daily or 7.5mg/kg twice daily or 20-25 mg/kg thrice weekly. Children:Intravenous amikacin 15-30 mg/kg once daily, maximum dose 1500mg
Trial: NCT04310930
Drug: Tigecycline
RxNorm normalized name: Tigecycline
DrugBank: Tigecycline (DB00560)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adults: Intravenous Tigecycline 25 mg increasing by 5 mg every two doses until either maximum dose reached (50mg) or until patient is unable to tolerate twice daily. Children (≥8 years of age) intravenous tigecycline: Day 1- 0.6mg/kg twice daily to a maximum of 25mg. Day 2- 0.6mg/kg (maximum 25mg) in the morning, 1.2 mg/kg (maximum 50mg) at night. Day 3- 1.2mg/kg (maximum 50 mg) twice daily
Trial: NCT04310930
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Adults: Oral azithromycin 500mg (≥40kg) once daily, (\<40kg) 250mg once daily.During consolidaiton: 500mg (≥40kg) thrice weekly, (\<40kg) 250mg thrice weekly.~Children: Oral azithromycin:10mg/kg (maximum 500mg) once daily. During consolidation 10mg/kg once daily maximum 500mg.
Trial: NCT04310930
Drug: Clarithromycin
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adult: If azithromycin is poorly tolerated use oral clarithromycin 500mg twice daily.Children: If azithromycin is poorly tolerated use oral clarithromycin. In children 1 month old- 11years of age the following dosing applies: \<8kg: 7.5mg/kg twice daily, maximum dose 62.5mg, 8-11kg: 62.5mg twice daily, maximum dose 62.5mg, 12-19 kg: 125mg twice daily, maximum dose 125mg, 20-29 kg: 187.5mg twice daily, maximum dose 187.5mg, 30-40 kg: 250mg twice daily, maximum dose 250mg, Children 12-18 years of age: 500 mg twice daily
Trial: NCT00787722
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: A medication used as chemotherapy and to suppress the immune system
Trial: NCT04310930
Drug: Amikacin
RxNorm normalized name: amikacin
DrugBank: Amikacin (DB00479)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: adult: Inhaled amikacin 500mg twice daily. Children: Inhaled amikacin 500mg twice daily
Trial: NCT04310930
Drug: co-trimoxazole
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral Co-trimoxazole (TMP-SMX) 160/800mg twice daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral co-trimoxazole 5mg TMP/kg maximum dose of 160mg TMP/ 800mg SMX twice daily.
Trial: NCT04310930
Drug: Doxycycline
RxNorm normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Adult: during consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin, bedaquiline or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline 100mg once daily. Children: During consolidation in combination with one to three oral antibiotics (co-trimoxazole, doxycycline, moxifloxacin or rifabutin) guided by participant susceptibility and tolerance. Oral doxycycline (ages ≥ 8 years) 2mg/kg once daily maximum dose 100mg.
Trial: NCT03688711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for dasiglucagon
Trial: NCT00873093
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given IV 60 mg/m2/dose on Day 1
Trial: NCT00873093
Drug: therapeutic hydrocortisone
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 8,15, 22 and 29 Block 2: Days 1 and 22
Trial: NCT00873093
Drug: methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IT (8mg - 15mg) Age-based dosing Block 1: Days 15 and 29 Block 2: Days 1 and 22
Trial: NCT00873093
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given IV 440 mg/m2/dose on Days 1-5
Trial: NCT00873093
Drug: leucovorin calcium
RxNorm normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Given PO or IV 15mg/m2/dose q6h x 3 doses
Trial: NCT00873093
Drug: High Dose MTX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV 5000 mg/m2/dose Block 2: Day 22
Trial: NCT00253409
Drug: chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03108287
Drug: RAK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg twice-daily
Trial: NCT03108287
Drug: RBAK therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: rabeprazole 20mg, amoxicillin 1g and clarithromycin 500mg, bismuth subcitrate 360mg twice-daily
Trial: NCT04725877
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: A placebo (Tris NaCl Sucrose formulation buffer) given by subcutaneous injection.
Trial: NCT03972215
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Control
Trial: NCT00312975
Drug: CP-675,206
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given intravenously every 3 months
Trial: NCT00312975
Drug: best supportive care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: As per investigator discretion. Excludes chemotherapy or other anti-cancer therapy
Trial: NCT03603197
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, solution for injection; doses: 0.07 mL/kg body weight intramuscularly once daily for 32 consecutive days
Trial: NCT01729897
Drug: Fentanyl
RxNorm normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT01686945
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo semaglutide. For oral administration.
Trial: NCT01686945
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo semaglutide with carrier. For oral administration.
Trial: NCT03025113
Drug: ketoprofen and cyclobenzaprine association
RxNorm normalized name: Ketoprofen
DrugBank: Ketoprofen (DB01009)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: The patient will take 2 tablets (Combination of ketoprofen and cyclobenzaprine), oral, per day, each 12h.
Trial: NCT00241007
Drug: VALSARTAN, VALSARTAN+HYDROCHLOROTHIAZIDE
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02521363
Drug: anthracycline and taxane based chemotherapy
RxNorm normalized name: Anthracyclines and related substances
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional, standard of care neoadjuvant chemotherapy delivered irrespective of device readout
Trial: NCT03977987
Drug: nucleos(t)ide analogue
RxNorm normalized name: gonadotropin releasing factor analog-diphtheria toxoid conjugate Injectable Solution [Improvest]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pregnant women in this group agree to receive nucleos(t)ide analogue (tenofovir or telbivudine) daily from the 28 weeks of pregnancy to delivery.
Trial: NCT00559312
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo Diskus inhaler, twice daily, 6-week duration
Trial: NCT00250445
Drug: MK0663, etoricoxib
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00250445
Drug: Comparator: Diclofenac sodium
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02212925
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03604848
Drug: WHO-approved MDR-TB regimen
RxNorm normalized name: Anacin Aspirin Regimen
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
Trial: NCT03604848
Drug: NGS-guided regimen: Regimen A
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
Trial: NCT03604848
Drug: NGS-guided regimen: Regimen B
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pyrazinamide 33-50kg 1000-1750 mg daily, 51-70kg 1750-2000 daily, \>70kg 2000-2500mg daily; Amikacin 600mg daily ; Moxifloxacin 33-50kg 400 mg daily, 51-70kg 600mg daily, \>70kg 800mg daily; Prothionamide 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily ; Cycloserine 33-50kg 500 mg daily, 51-70kg 750 daily, \>70kg 1000 mg daily All treatment is taken daily.
Trial: NCT03604848
Drug: NGS-guided regimen: Regimen C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Based on the drug susceptibility test results, the resistant drug(s) will be replaced by the other WHO recommended drugs for MDR-TB such as linezolid, clofazimine or ethambutol.~The dose of linezolid, clofazimine or ethambutol as follows:~Linezolid: 600 mg daily, clofazamine: 33-50kg 50 mg daily, 51-70kg 100 daily, \>70kg 100 mg daily; ethambutol: 33-50kg 800 mg daily, 51-70kg 800 daily, \>70kg 1200 mg daily;
Trial: NCT02489448
Drug: MEDI4736
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The investigational product is MEDI4736 which will be supplied in glass vials containing 500 mg of liquid solution at a concentration of 50 mg/mL for intravenous (IV) administration.~Routine, standard of care chemotherapy will be given together with the investigational product and will include weekly nab-paclitaxel x12 treatments followed by every two-week doxorubicin, cyclophosphamide (ddAC) x 4 treatments.
Trial: NCT02586311
Drug: CKD-330 16/5mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT02586311
Drug: CKD-330 16/5mg Placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day, 8 weeks
Trial: NCT01562717
Drug: Ibuprofen
RxNorm normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 3 times a day
Trial: NCT01562717
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 times a day
Trial: NCT01409915
Drug: Saline -- placebo comparator
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection
Trial: NCT02010905
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT02250300
Drug: MLN9708 (2.3 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.3 mg
Trial: NCT02250300
Drug: MLN9708 (4.0 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.0 mg
Trial: NCT02250300
Drug: MLN9708 (3.0 mg)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3.0 mg
Trial: NCT00535431
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline nebulised, twice daily for 28 days
Trial: NCT04110873
Drug: Placebo oral capsule
RxNorm normalized name: Placebo Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: patients will receive placebo per day (QD) on Day 1 for 12 weeks
Trial: NCT01008410
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matching to budesonide will be administered as per the schedule specified in the respective arm.
Trial: NCT01826981
Drug: LDV/SOF
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ledipasvir/sofosbuvir (LDV/SOF) (90 /400 mg) fixed-dose combination (FDC) tablet administered orally once daily
Trial: NCT01826981
Drug: SOF
RxNorm normalized name: Kasof
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SOF 400 mg tablet administered orally once daily
Trial: NCT01302067
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral, 1 tablet per day, 12 weeks duration